Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi® a highly purified, doubly inactivated FVIII/VWF concentrate

Therapy with factor VIII/von Willebrand factor (FVIII/VWF) concentrate is the mainstay therapy in patients with von Willebrand disease (VWD) unresponsive to desmopressin. There are several commercially available FVIII/VWF concentrates that have been tested in VWD patients. We retrospectively analize...

Full description

Saved in:
Bibliographic Details
Published in:Haemophilia : the official journal of the World Federation of Hemophilia 2008-09, Vol.14 (5), p.963-967
Main Authors: HERNANDEZ-NAVARRO, F., QUINTANA, M., JIMENEZ-YUSTE, V., ALVAREZ, M. T., FERNANDEZ-MORATA, R.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
bleeding
Blood Loss, Surgical - prevention & control
Child
Child, Preschool
Drug Combinations
Drug Evaluation
Factor VIII - therapeutic use
Fanhdi
Female
FVIII/VWF concentrates
Hemorrhage - drug therapy
Hemorrhage - etiology
Hemostasis, Surgical - methods
Humans
Male
Middle Aged
Retrospective Studies
Treatment Outcome
Virus Inactivation
von Willebrand disease
von Willebrand Diseases - complications
von Willebrand Diseases - drug therapy
von Willebrand Factor - therapeutic use
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Therapy with factor VIII/von Willebrand factor (FVIII/VWF) concentrate is the mainstay therapy in patients with von Willebrand disease (VWD) unresponsive to desmopressin. There are several commercially available FVIII/VWF concentrates that have been tested in VWD patients. We retrospectively analized the clinical efficacy in bleeding episodes and surgery of a highly purified FVIII/VWF complex with two inactivation steps (Fanhdi®) in VWD patients. Sixty patients were included in the study. Treatment schedule consisted of one or more doses (standard dose 40 IU/kg body weight of FVIII) of Fanhdi®. One hundred and fifty bleeding episodes were treated. These were: 28 serious bleedings; 92 moderate and 30 mild. An excellent clinical efficacy in almost 95% of cases was observed. Fanhdi® was administered during 66 surgical procedures (38 major and 28 minor) with an overall efficacy of 98%. Fanhdi® a highly purified, doubly virus‐inactivated FVIII/VWF concentrate, with a high content of active VWF and an excellent record of clinical safety, is a valid choice in treating VWD.
ISSN:1351-8216
1365-2516
DOI:10.1111/j.1365-2516.2008.01784.x